Last mentioned: Mar 5, 2026
Stevanato Group reported a 50% surge in GLP-1 related revenue for 2025, underscoring the massive impact of the weight-loss drug market on pharmaceutical supply chains. Conversely, medical device maker Pulmonx is undergoing a significant transition following a 50% turnover in its sales organization and a dip in U.S. quarterly revenue.
Stevanato Group reported robust 2025 results fueled by a 50% surge in GLP-1 related revenue, while medical device maker Pulmonx initiated aggressive cost-cutting measures following a U.S. revenue decline. The divergence highlights a shifting healthcare landscape where specialized biopharma supply chains are outperforming traditional niche medical devices.
A wave of Q4 2025 earnings reports reveals a dual-track workforce strategy: aggressive headcount reductions in legacy sectors contrasted with AI-driven efficiency in high-growth software firms. Companies like Riskified and Pulmonx are leading a trend toward leaner, more specialized teams as organizations pivot toward high-margin recurring revenue models.